Nutropin adverse event reports that FDA received

Name: Reaction terms in FDA adverse event reports that name Nutropin
Creator: Reported Reactions
License: https://creativecommons.org/publicdomain/zero/1.0/

Name type: Product name as reported

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Drug reports received through 30 Jun 2026. Device reports have a separate cutoff, 30 Sep 2026. Why a report count is not a rate.

Reports on file

From February 2004 to May 2026, FDA received 3,906 adverse event reports that name Nutropin. The name is as reporters wrote it. In these reports the drug is a suspect or interacting product.

In the same period, 166 further reports name it only as a concomitant medicine. The counts on this page do not include these reports.

FDA received 13 reports in the 12 months to June 2026 and 128 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 13 (under 0.1%) name Nutropin. Reports for male patients were 54.2% of the reports that name Nutropin and 34.6% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate. A count of reports is not a count of events or of patients, because one event can have more than one report.

There are many instances of duplicative reports and some reports do not contain all the necessary information.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Suspect product

FDA records each drug in a report as suspect, concomitant or interacting. This page counts the reports in which Nutropin is suspect or interacting. FDA says:

Any number of the drugs may be marked as suspect if thought to be responsible for one or more of the reactions, but that information is not validated.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Since the last update

FDA says:

Many factors can influence whether or not an event will be reported, such as the time a product has been marketed and publicity about an event.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The information in these reports cannot be used to estimate the incidence (occurrence rates) of the events reported.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

The latest update of the FDA data, recorded on 28 Oct 2026, changed no count of this page.

In April to June 2026, FDA received 1 report that names Nutropin.
In January to March 2026, FDA received 0.
In April to June 2025, FDA received 5.

April to June 2026 is the latest closed quarter in the data. A closed quarter is a quarter for which the FDA files have most of the reports.

All updates Feed of updates (RSS)

Reaction lookup

These are the reaction terms that the reports record, with the number of reports for each term. Type a term or a plain word to find its count.

What this list leaves out

The table lists the 208 reaction terms that 5 or more reports record. A term with fewer than 5 reports is not in the table.

The site keeps reaction terms for 3,903 of the 3,906 reports (99.9%).

The reports of the other years are not in the counts.

So a count in the table can be lower than the count of FDA.

Find a reaction term

The table shows the first 50 of 208 terms.

Reaction terms in the reports that name Nutropin, most reports first
Reaction term (MedDRA) and plain meaning	Reports	Share of the 3,906 reports
No adverse eventno adverse event was reported	576	14.7%
Malaisegeneral feeling of being unwell	274	7%
Headachehead pain	265	6.8%
Injection site painpain where the injection was given	257	6.6%
Painpain, site not specified	210	5.4%
Arthralgiajoint pain	186	4.8%
Fatiguetiredness	150	3.8%
Off label useused for a purpose or in a way not on the label	149	3.8%
Product dose omission issuea dose was missed	130	3.3%
Product storage errorthe product was stored wrongly	110	2.8%
Drug ineffectivethe medicine did not work as expected	85	2.2%
Incorrect dose administeredthe wrong dose was given	77	2%
Vomitingbeing sick	70	1.8%
Pain in extremitypain in an arm or leg	69	1.8%
Deaththe patient died; cause not stated by this term	68	1.7%
Weight increasedweight gain	67	1.7%
Pyrexiafever	65	1.7%
Growth retardation	61	1.6%
Drug dose omissiona dose was missed	56	1.4%
Product quality issuea problem with the product itself	53	1.4%
Nauseafeeling sick	52	1.3%
Rashskin rash	52	1.3%
Clear cell renal cell carcinoma	47	1.2%
Lymphoproliferative disorder	47	1.2%
Device issuea problem with the device	46	1.2%
Burning sensationa burning feeling	42	1.1%
Astheniaweakness or lack of energy	41	1%
Contusiona bruise	41	1%
Cough	39	1%
Device malfunctionthe device did not work properly	38	1%
Back pain	37	0.9%
Depressionlow mood	37	0.9%
Dizzinesslight-headedness or unsteadiness	37	0.9%
Peripheral swellingswelling of the arms or legs	37	0.9%
Diarrhoealoose or frequent stools	35	0.9%
Insomniadifficulty sleeping	35	0.9%
Underdoseless than the intended dose	35	0.9%
Product temperature excursion issue	34	0.9%
Injection site bruisingbruising where the injection was given	33	0.8%
Device defective	32	0.8%
Weight decreasedweight loss	31	0.8%
Product complaint	30	0.8%
Product use in unapproved indicationused for a purpose not on the label	30	0.8%
Swelling	28	0.7%
Intentional product use issuedeliberate use not as intended	27	0.7%
Intercepted product storage error	27	0.7%
Medication errora mistake in prescribing, dispensing or taking a medicine	27	0.7%
Myalgiamuscle pain	27	0.7%
Sudden deatha sudden death	26	0.7%
Wrong technique in product usage processthe product was used in the wrong way	26	0.7%

Download all 208 terms of Nutropin (CSV)

The counts add to more than 3,906 reports, because one report can record more than one term. FDA says:

No individual drug is connected to any individual reaction. When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The CSV file has the same rows and the same limits. Its last row is a note that says so.

MedDRA term

The person who codes a report selects the preferred term that agrees best with the description of the reporter. The words under a term are the plain meaning that this site gives.

Not the label

The FDA-approved label of a product lists its adverse reactions. See the official pages at the end of this page.

Outcomes by year

The table gives the outcomes that the reporters gave, in the terms of FDA.

Outcomes in the reports that name Nutropin, by the year of the openFDA file that holds the report

The table continues to the right.

Year of the openFDA file	Reports	Serious	Death	Life-threatening	Hospitalization (initial or prolonged)	Disability or Permanent Damage	Other Serious (Important Medical Events)	Not serious
2004	26	18	2	2	4	1	13	8
2005	28	20	1	1	8	1	13	8
2006	44	37	4	2	11	1	24	7
2007	70	66	7	0	4	1	54	4
2008	64	62	46	4	4	1	13	2
2009	33	33	6	1	5	1	24	0
2010	23	23	2	2	5	1	17	0
2011	19	19	2	0	7	0	10	0
2012	80	74	25	2	35	0	25	6
2013	58	57	3	0	16	0	40	1
2014	81	80	6	1	21	0	60	1
2015	153	151	37	1	51	0	75	2
2016	90	34	2	0	11	0	23	56
2017	1,733	41	1	0	12	1	28	1,692
2018	66	35	1	0	18	0	17	31
2019	127	48	3	0	13	0	34	79
2020	109	66	6	3	17	0	51	43
2021	214	60	6	0	14	2	39	154
2022	349	48	1	0	12	0	35	301
2023	313	9	3	0	1	0	7	304
2024	195	8	0	0	5	1	4	187
2025	28	9	0	1	3	0	9	19
2026	3	2	0	0	1	0	2	1

An outcome in a report is not proof that the drug was the cause. The reporter gives the outcome, and FDA does not verify it. FDA says:

The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

The six headings with the names of FDA are the outcome terms of FDA. A report can have more than one outcome. The columns Serious and Not serious are the two values of the openFDA field serious. For the value serious, openFDA gives this description:

The adverse event resulted in death, a life threatening condition, hospitalization, disability, congenital anomaly, or other serious condition
Source: openFDA, Drug adverse event fields (YAML reference). The site read the page on 2 Oct 2026.

The year is the year of the openFDA file that holds the latest version of the report. It is not always the year in which FDA first received the report. The chart of the next section uses the year of first receipt. The latest year is not complete.

Reports by year and month

Reports that name Nutropin, by the year in which FDA received them

The column of 2026 has an outline, because the year is not complete. It has the reports that FDA received through June 2026 only.

Show the figures of the chart as a table

Reports that name Nutropin, by the year in which FDA received them
Year	Reports
2004	19
2005	28
2006	41
2007	76
2008	64
2009	34
2010	23
2011	18
2012	197
2013	66
2014	83
2015	40
2016	90
2017	1,731
2018	66
2019	138
2020	102
2021	217
2022	361
2023	303
2024	186
2025	22
2026	1

Reports that name Nutropin, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Why a count moves

A count moves for many reasons. The guide gives FDA's words about them.

Patients and reporters

Age of the patient in the reports that name Nutropin
Age	Reports	Share
Under 2	31	0.8%
2 to 11	501	12.8%
12 to 17	579	14.8%
18 to 44	102	2.6%
45 to 64	92	2.4%
65 to 74	35	0.9%
75 and over	18	0.5%
Age not given	2,548	65.2%

Sex of the patient in the reports that name Nutropin
Sex	Reports	Share
Female	1,464	37.5%
Male	2,118	54.2%
Unknown or not given	324	8.3%

Type of reporter in the reports that name Nutropin
Reporter	Reports	Share
Physician	1,166	29.9%
Pharmacist	107	2.7%
Other health professional	327	8.4%
Lawyer	1	under 0.1%
Consumer or non-health professional	2,265	58%
Not given	40	1%

Age and sex are as the report gives them. The reporter is the primary source in the report. 93.7% of the reports give the United States as the country.

Reason for use

Reason for use (indication) that the reports of Nutropin record
Indication as recorded (MedDRA)	Reports	Share
Hypopituitarism	557	14.3%
Dwarfism	546	14%
Growth hormone deficiency	487	12.5%
Body height below normal	168	4.3%
Chronic kidney disease	98	2.5%
Short stature	91	2.3%

The reporter fills in the indication, and the field is often empty. Each share is of all 3,906 reports.

Drugs in the same reports

Other drugs that the reports of Nutropin name, in any role, in order of name
Drug	Reports that name the two
Amlodipine	59
Azathioprine	52
Ferrous fumarate	44
Metformin	50
Methotrexate	47
Prednisone	102
Ranitidine	46
Sulfamethoxazole	47
Synthroid	124
Testosterone	71

The table has the 10 drug names that these reports name most. Two names in one report says only that the report recorded the two. It says nothing about the part of a product in the event.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pages near this one

Nutrineal Pd4 next in the A to Z list
Nutropin Aq next in the A to Z list
Nutrineal next in the A to Z list
Nuvaring next in the A to Z list
Nurtec Odt next in the A to Z list
Nuvigil next in the A to Z list
Nurofen next in the A to Z list
Nuzyra next in the A to Z list
Nuplazid next in the A to Z list
Nystatin next in the A to Z list
Nulojix next in the A to Z list
Obinutuzumab next in the A to Z list

These links are for navigation. No count selected them.

Official pages

DailyMed labels for NutropinThe labels (prescribing information) that have this name, at the National Library of Medicine.
MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Nutropin: adverse event reports that FDA received. https://reportedreactions.com/drug/nutropin/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

A report is in the count when it names Nutropin as a suspect or interacting product. The 166 reports that name it only as a concomitant medicine are not in the count. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

Do these reports show that Nutropin was responsible for the reactions?

No. FDA says:

For any given report, there is no certainty that a suspected drug caused the event.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

A reaction can relate to the condition that the drug treats, to other medicines, or to something else.

Is this the list of reactions on the label of Nutropin?

No. It is a count of what people reported to FDA: 3,906 reports from February 2004 to May 2026. The FDA-approved label of a product lists its adverse reactions. The official pages at the end of this page link to the labels.

Who sent these reports?

Consumer or non-health professional (58%), physician (29.9%) and other health professional (8.4%). These are the types of reporter for the reports that name this drug.

If a manufacturer receives an adverse event report, it is normally required to send the report to FDA.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

How does a person report an adverse event?

FDA runs MedWatch, a program that takes voluntary reports from health professionals, patients and consumers. The guide on how to report has the links.

To the top of the page